{"id":44101,"date":"2025-10-22T19:58:49","date_gmt":"2025-10-22T11:58:49","guid":{"rendered":"https:\/\/flcube.com\/?p=44101"},"modified":"2025-10-22T19:58:50","modified_gmt":"2025-10-22T11:58:50","slug":"astrazeneca-daiichi-sankyo-announce-11-2-pcr-gain-with-enhertu-in-destiny%e2%80%91breast11-at-esmo-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44101","title":{"rendered":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025"},"content":{"rendered":"\n<p><strong>AstraZeneca (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NASDAQ\">NASDAQ: AZN<\/a>)<\/strong> and <strong>Daiichi Sankyo (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO: 4568<\/a>)<\/strong> disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the <strong>2025 European Society for Medical Oncology (ESMO) Congress<\/strong>. The study demonstrated that <strong>Enhertu (trastuzumab deruxtecan, T\u2011DXd)<\/strong>, administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-study-highlights\"><strong>Study Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>T\u2011DXd\u202f+\u202fTHP<\/th><th>ddAC\u2011THP (Control)<\/th><th>\u0394<\/th><\/tr><\/thead><tbody><tr><td><strong>pCR rate<\/strong><\/td><td><strong>67.3\u202f%<\/strong><\/td><td>56.3\u202f%<\/td><td><strong>+11.2\u202f%<\/strong><\/td><\/tr><tr><td><strong>HR\u207a subgroup<\/strong><\/td><td>61.4\u202f%<\/td><td>52.3\u202f%<\/td><td>+9.1\u202f%<\/td><\/tr><tr><td><strong>HR\u207b subgroup<\/strong><\/td><td>83.1\u202f%<\/td><td>67.1\u202f%<\/td><td>+16.0\u202f%<\/td><\/tr><tr><td><strong>Residual Cancer Burden 0\u202f+\u202fI<\/strong><\/td><td>81.3\u202f%<\/td><td>69.1\u202f%<\/td><td>+12.2\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Overall improvement<\/strong>: 67.3\u202f% vs. 56.3\u202f% pCR.<\/li>\n\n\n\n<li><strong>Subgroup benefit<\/strong>: Significant gains seen in both hormone\u2011receptor positive and negative cohorts.<\/li>\n\n\n\n<li><strong>Post\u2011surgery outcome<\/strong>: 81.3\u202f% of the T\u2011DXd arm achieved RCB\u202f0\u202f+\u202fI versus 69.1\u202f% in the control arm.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-about-enhertu-t-dxd\"><strong>About Enhertu (T\u2011DXd)<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: HER2\u2011targeting antibody\u2011drug conjugate (ADC) combining a humanized anti\u2011HER2 mAb with the topoisomerase\u2011I inhibitor DXd via a cleavable tetrapeptide linker.<\/li>\n\n\n\n<li><strong>Technology<\/strong>: Built on Daiichi Sankyo\u2019s proprietary DXd ADC platform; the most advanced ADC in AstraZeneca\u2019s oncology pipeline.<\/li>\n\n\n\n<li><strong>Global Approval<\/strong>: Licensed in <strong>>85 countries<\/strong> for HER2\u2011positive metastatic or early\u2011stage breast cancer after \u22651 prior anti\u2011HER2 therapy.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implications-for-clinical-practice\"><strong>Implications for Clinical Practice<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neoadjuvant Advantage<\/strong>: The higher pCR rate suggests a stronger likelihood of long\u2011term disease control.<\/li>\n\n\n\n<li><strong>Broad Applicability<\/strong>: Benefit spans HR\u2011positive and HR\u2011negative disease, supporting use across the HER2\u2011positive spectrum.<\/li>\n\n\n\n<li><strong>Strategic Collaboration<\/strong>: Demonstrates the synergistic potential of combining AstraZeneca\u2019s ADC platform with Daiichi Sankyo\u2019s drug\u2011delivery expertise.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\"><strong>Forward\u2011Looking Statements<\/strong><\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at&#8230;<\/p>\n","protected":false},"author":1,"featured_media":44102,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,35,130,16,17,194,871,978],"class_list":["post-44101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-adc-xdc","tag-astrazeneca","tag-cancer","tag-clinical-trial-results","tag-daiichi-sankyo","tag-nasdaq-azn","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=44101\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=44101\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-22T11:58:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-22T11:58:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025\",\"datePublished\":\"2025-10-22T11:58:49+00:00\",\"dateModified\":\"2025-10-22T11:58:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2204.webp\",\"keywords\":[\"Academic conference\",\"ADC \\\/ XDC\",\"AstraZeneca\",\"Cancer\",\"Clinical trial results\",\"Daiichi Sankyo\",\"NASDAQ: AZN\",\"TYO: 4568\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44101#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=44101\",\"name\":\"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2204.webp\",\"datePublished\":\"2025-10-22T11:58:49+00:00\",\"dateModified\":\"2025-10-22T11:58:50+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=44101\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2204.webp\",\"width\":1080,\"height\":608,\"caption\":\"AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=44101#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=44101","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025","og_description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.","og_url":"https:\/\/flcube.com\/?p=44101","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-22T11:58:49+00:00","article_modified_time":"2025-10-22T11:58:50+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=44101#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=44101"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025","datePublished":"2025-10-22T11:58:49+00:00","dateModified":"2025-10-22T11:58:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=44101"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=44101#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","keywords":["Academic conference","ADC \/ XDC","AstraZeneca","Cancer","Clinical trial results","Daiichi Sankyo","NASDAQ: AZN","TYO: 4568"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=44101#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=44101","url":"https:\/\/flcube.com\/?p=44101","name":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=44101#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=44101#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","datePublished":"2025-10-22T11:58:49+00:00","dateModified":"2025-10-22T11:58:50+00:00","description":"AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase\u202fIII DESTINY\u2011Breast11 results at the 2025 European Society for Medical Oncology (ESMO) Congress. The study demonstrated that Enhertu (trastuzumab deruxtecan, T\u2011DXd), administered sequentially to the THP regimen (paclitaxel, trastuzumab, pertuzumab) as a neoadjuvant therapy, produced a clinically meaningful 11.2\u202f% rise in pathological complete response (pCR) rates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=44101#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=44101"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=44101#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","width":1080,"height":608,"caption":"AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=44101#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca &amp; Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY\u2011Breast11 at ESMO 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=44101"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44101\/revisions"}],"predecessor-version":[{"id":44103,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/44101\/revisions\/44103"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/44102"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=44101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=44101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=44101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}